Completed PHASE4 INTERVENTIONAL 2-arm NCT02796105

Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors

Sponsor: Fundació Privada Eugin

Conditions Infertility

Interventions Orgalutran Progevera

Updated 6 times since 2017 Last updated: Sep 12, 2017 Started: Jun 30, 2016 Primary completion: Jul 31, 2017 Completion: Jul 10, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Infertility and is currently completed. Fundació Privada Eugin leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Oct 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE4

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundació Privada Eugin

Data source: Fundació Privada Eugin

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain